Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Califf Gets Unanimous Committee Vote Supporting FDA Commissioner Bid

This article was originally published in Clinica

Executive Summary

After being thoroughly questioned, Robert Califf won a unanimous vote in support of his bid to become the next FDA commissioner from the Senate Health, Education, Labor and Pensions Committee on Jan. 12. Califf, who currently serves as FDA's deputy commissioner for medical products and tobacco, still requires full Senate approval and is likely to find some challenges there.

You may also be interested in...



Califf Clears First Senate Hurdle, But Could FDA’s Abortion Pill Access Decision Be A Headache?

Robert Califf’s nomination to be the next US FDA commissioner squeaked out of the Senate health committee, but a significant number of Republicans are against his confirmation over the agency’s recent decisions on abortion drugs.

Life After NASH For CymaBay: An Interview With CEO Sujal Shah

With up to $100m from Abingworth and a recent $75m FOPO, CymaBay has runway to await pivotal data in primary biliary cholangitis in 2023 for seladelpar, after the candidate failed in NASH. It sees a significant market opportunity in the second-line setting cornered by Intercept.

FDA, Industry To Miss MDUFA V Congressional Deadline; Insiders At Odds Over Future Of Deal

The US agency and the medtech industry still have significant disagreements, which means they will miss a 15 January deadline to send the MDUFA V user-fee deal to Congress. Insiders disagree, however, on how severe those disagreements are and when a deal can be reached.

Topics

UsernamePublicRestriction

Register

MT103126

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel